Our transcriptomic analyses demonstrate that cell lines weakly responsive to the combination treatments exhibited higher expression of genes in cancer hallmark pathways, such as EMT, PI3K/AKT/mTOR signaling and TGFβ signaling. This evidence concerns the gene TGFB1 and cancer.